Synthesis, computational studies and preliminary pharmacological evaluation of 2-[4-(aryl substituted) piperazin-1-yl] N, N-diphenylacetamides as potential antipsychotics

European Journal of Medicinal Chemistry

Volumn 46, Issue 9, 2011, Pages 4753-4759

  Kumar, Sushil ^a   Wahi, A K ^a   Singh, Ranjit ^b  

^a Drug Design and Medicinal Chemistry Research Laboratory   (India)

^b SHOBHIT UNIVERSITY   (India)

Author keywords

Antipsychotic activity; Arylpiperazines; Computational studies; Dopamine and Serotonin antagonists; N, N diphenylacetamide

Indexed keywords

2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (2,3 DIMETHYLPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (3 METHOXYPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (3, 4 DICHLOROPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (4 METHYLPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (4 NITROPHENYL)PIPERAZIN 1 YL] N,N DIPHENYLACETAMIDE; 2 [4 (PHENYL)PIPERAZIN 1 YL] N,N DIPHENYL ACETAMIDE; 5 HYDROXYTRYPTOPHAN; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; KETANSERIN; PIPERAZINE DERIVATIVE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG SYNTHESIS; HEAD TWITCH; MOUSE; NONHUMAN;

ACETAMIDES; ANTIPSYCHOTIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; PIPERAZINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 80052957717     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.07.028     Document Type: Article

References (35)

1. M.D. Jibson, I.D. Glick, and R. Tandon Schizophrenia and other psychotic disorders Focus 2 2004 17 30
2. G.P. Reynolds Developments in the drug treatment of schizophrenia Trends Pharmacol. Sci. 13 3 1992 116 121
3. C.A. Altar, A.R. Martin, A. Thurkauf, and D.J. Abraham Burger's Medicinal Chemistry and Drug Discovery sixth ed. 2003 John Wiley & Sons New Jersey pp. 599
4. G.M. Simpson, E.H. Pi, and J.J. Sramek Adverse effects of antipsychotic agents Drugs 21 1981 138 151
5. S.M. Stahl Essential Psychopharmacology second ed. 2000 Cambridge University Press Cambridge pp. 401
6. H.Y. Meltzer Commentary on clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia Psychopharmacology 99 1989 518
7. T. Kuroki, N. Nagao, and T. Nakahara Neuropharmacology of second generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis Prog. Brain Res. 172 2008 199 212
8. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1159 1172
9. H.Y. Meltzer, S. Matsurba, and J.C. Lee The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs Psychopharmacol. Bull. 25 1989 390
10. M. Tomic, M. Kundakovic, B. Butorovic, B. Janac, D. Andric, G. Roglic, D. Ignjatovic, and S. Kostic-Rajacic Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential Bioorg. Med. Chem. Lett. 14 2004 4263 4266
11. M. Kolaczkowski, P. Zajdel, O. Fhid, B. Duszynska, E. Tatarczynska, and M. Pawlowski Synthesis and 5-HT1A/5-HT2A activity of some butyl analogs in the group of Phenyl piperazine alkyl pyrimido [2,1-f] theophyllines Pharmacol. Rep. 57 2005 229 235
12. 2A receptors Bioorg. Med. Chem. Lett. 113 2003 175 178
13. 2A receptor activity of new N-[3-(4- phenylpiperazin-1-yl)-propyl] derivatives of 3-spiro-cyclohexanepyrrolidine-2, 5-dione and 3-spiro-β-tetralonepyrrolidine-2, 5-dione Pol. J. Pharmacol. 55 2003 553 557
14. G. Neves, R. Menegatti, C.B. Antonio, L.R. Grazziottin, R.O. Vieira, S.M.K. Rates, F. Noel, E.J. Barreiro, and C.A.M. Fraga Searching for multi-target antipsychotics: discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors Bioorg. Med. Chem. Lett. 18 2010 1925 1935
15. 2A receptors Eur. J. Med. Chem. 37 2002 503 510
16. 2 receptors J. Med. Chem. 42 1999 490 496
17. M.L. Lopez-Rodriguez, M.J. Morcillo, E. Fernandez, E. Porras, L. Orensanz, M.E. Beneytez, J. Manzanares, and J.A. Fuentes Synthesis and structure-activity relationships of a new model of arylpiperazines J. Med. Chem. 44 2001 186 197
18. A. Hackling, R. Gosh, S. Perachon, A. Mann, H.D. Holtje, C.G. Wermuth, J.C. Schwartz, W. Sippl, P. Sokoloff, and H. Stark N-(ω-(4-(2- methoxyphenyl) piperazin-1-yl) alkyl) carboxamides as dopamine D2 and D3 receptor ligands J. Med. Chem. 46 2003 3883 3899
19. 3 receptor ligands J. Med. Chem. 45 2002 5727 5735
20. A.J. Bojarski, B. Kuran, J. Kossakowski, A. Koziol, E. Jagiello-Wojtowicz, and A. Chodkowska Synthesis and serotonin receptor activity of the arylpiperazine alkyl/propoxy derivatives of new azatricycloundecanes Eur. J. Med. Chem. 44 2009 152 164
21. 7 receptor activity J. Med. Chem. 51 2008 5813 5822
22. L. Carro, E. Ravina, E. Dominguez, J. Brea, M.I. Loza, and C.F. Masaguer Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif Bioorg. Med. Chem. Lett. 19 2009 6059 6062
23. A. Bali, S. Malhotra, H. Dhir, A. Kumar, and A. Sharma Synthesis and evaluation of 1-(quinoliloxypropyl)-4-arylpiperazines for atypical antipsychotic effect Bioorg. Med. Chem. Lett. 19 2009 3041 3044
24. H. Waterbeemed, G. Camenishch, G. Folkers, J.R. Chretien, and O.A. Raevsky Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors J. Drugs Target 6 1998 151 165
25. J. Kelder, P.D.J. Grootenhuis, D.M. Bayada, L.P.C. Delbressine, and J.P. Ploemen Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 16 1999 1514 1519
26. A. Bali, K. Sharma, A. Bhalla, S. Bala, D. Reddy, A. Singh, and A. Kumar Synthesis, evaluation and computational studies on a series of acetophenone based 1- (aryloxypropyl)-4-(chloroaryl) piperazines as potential atypical antipsychotics Eur. J. Med. Chem. 45 6 2010 2656 2662
27. I.W. Chung, N.A. Moore, W.K. Oh, M.F.O. Neill, J.S. Ahn, J.B. Park, U.G. Kang, and Y.S. Kim Behavioural pharmacology of polygalasaponins indicates potential antipsychotic efficacy Pharmacol. Biochem. Behav. 71 2002 191 195
28. G. Campaini, S. Butini, S. Gemma, V. Nacci, C. Fattorussa, B. Catalanotti, G. Giorgi, A. Cagnatto, M. Goegan, T. Mennini, P. Minetti, M.A.D. Cesare, D. Mastroianni, N. Scafetta, M.A. Stasi, M. Castorina, L. Pacifici, O. Ghirardi, and P. TintiCarminati Pyrrolo[1,3] benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modelling, and biological studies J. Med. Chem. 45 2002 344 359
29. N.J. Hrib, J.G. Jurcak, D.E. Bregna, K.L. Burgher, H.B. Hartman, S. Kafka, L.L. Kerman, S. Kongsamut, J.E. Roehr, and M.R. Szewczak Structure-activity relationship of a series of novel (piperazinylbutyl) thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fiuorobenzo [b] thien-3-yl)-1-piperazinyl] butyl]-2, 5, 5-trimethyl-4-thiazolidinone maleate J. Med. Chem. 39 1996 4044 4057
30. 2A receptor antagonist S21357 Pharmacol. Biochem. Behav. 54 2 1996 509 516
31. S. Ferre, T. Guix, G. Prat, F. Jane, and M. Casas Is experimental catalepsy properly measured? Pharmacol. Biochem. Behav. 35 1990 753 777
32. S. Pemminati, V. Nair, P. Dorababu, H.N. Gopalakrishna, and M.R.S.M. Pai Effect of ethanolic leaf extract of Ocimum sanctum on haloperidol-induced catalepsy in albino mice Ind. J. Pharmacol. 39 2007 87 89
33. H.G. Vogel Drug Discovery and Evaluation: Pharmacological Assay third ed. 2007 Springer 761 762
34. S. Shao, and J. Sun 2-Chloro-N, N-diphenylacetamide Acta Cryst. E 65 2009 1719
35. Chemsilico.com/CS-prBBB/BBBdata.html.